CAR T-cell therapy

Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Relapsed Childhood ALL / Immunotherapeutic Approaches for Relapsed or Refractory ALL

Chimeric antigen receptor (CAR) T-cell therapy is a therapeutic strategy for pediatric B-ALL patients with refractory disease or those in second or subsequent relapse. This treatment involves engineering T cells with a CAR that redirects T-cell specificity and function.[170] One widely utilized target of CAR-modified T cells is the CD19 antigen expressed on almost all normal B cells and most B-cell malignancies.

Source links and citations

Continue within this section

Toxicities associated with CAR T-cell therapy →CD19-targeted CAR T-cell therapy →CD22-targeted CAR T-cell therapy →Multiantigen targeted CAR T-cell therapy →

Publication references

Read the original reference and check its publication notices.

PubMed 23527958 · Original source

Preserved source evidence · Not medical advice